Ingredient · Evidence grade C
ERr 731 rhapontic rhubarb for menopause: evidence, studies and safety
Last updated · 4 studies summarized
C Short answer: ERr 731 is a rhapontic rhubarb root extract (the active in Estroven Complete) studied in perimenopausal women for occasional hot flashes and related symptoms*. The placebo-controlled trials come from one research group.
Key facts
| Evidence grade | C C (C+ for perimenopause) |
|---|---|
| Use studied | perimenopausal symptoms |
| Trials | 3 placebo RCTs by one research group (Heger 2006 n=109; Kaszkin-Bettag 2009 n=112; + earlier anxiety analysis) + Indian open-label |
| Participants | ~221+ randomized; MA 390 |
| What reviews conclude | Dubey 2024 MA (4 studies, 390 women; industry-affiliated authors): MRS -15 points vs control. |
| The Menopause Society (2023) | Not recommended (Level II) – placebo-arm retention only 12.7% in key RCT; open-label study. |
| Also known as | ERr 731, Rheum rhaponticum, Estrovera, Phytoestrol |
Grades: A strong · B moderate · C limited · D none or negative. How we grade.
Every study we reviewed
Each summary gives who took part, the dose, how long, the result compared with placebo or control, and who paid for it.
-
Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial.
109 perimenopausal women took the rhubarb-root extract ERr 731 (sold as Estrovera/Estroven Complete) or placebo for 12 weeks. Symptoms including hot flashes improved strongly. However, most women on placebo dropped out, which makes the comparison less reliable.
- Who
- 109 perimenopausal women
- Dose
- ERr 731 one tablet/day (4 mg)
- Duration
- 12 weeks
- Result
- MRS total and each symptom improved vs placebo (P<.0001); fewer and milder hot flushes from week 4; no endometrial changes. NAMS notes only 7/55 placebo completers.
- Funding
- Authors from Health Research Services Ltd; manufacturer (Dr. Loges) funding not stated in abstract. Industry-linked
-
Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms.
A second 12-week trial by the same research group (112 women) again found large improvements with ERr 731 versus placebo. Independent replication is still lacking.
- Who
- 112 perimenopausal women
- Dose
- ERr 731 one tablet/day
- Duration
- 12 weeks
- Result
- MRS total 27.0→12.4 vs 27.0→24.0 placebo (P<.0001); hot flushes reduced.
- Funding
- Same research group as the original trial; funding not stated in abstract. Industry-linked
-
Efficacy evaluation of standardized Rheum rhaponticum root extract (ERr 731 (®)) on symptoms of menopause: A systematic review and meta-analysis study.
A pooled analysis of 4 ERr 731 studies found large symptom reductions, but the analysis was written by staff of a company that sells the extract.
- Who
- 4 studies, 390 women
- Dose
- ERr 731
- Duration
- 12 weeks
- Result
- Pooled MRS reduction -15.1 points vs control (P<.001).
- Funding
- Lead authors from Sundyota Numandis (Indian distributor) – industry-affiliated. Industry-linked
-
Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer.
In German medical records, women prescribed ERr 731 were not more likely to be diagnosed with breast cancer than women who were not. This is observational, partly industry-linked data.
- Who
- 5,686 users vs 17,058 non-users (German records)
- Dose
- ERr 731 prescriptions
- Duration
- observational
- Result
- No increase in breast-cancer diagnosis (OR 1.01, 95% CI 0.81–1.26).
- Funding
- Two authors employed by Health Research Services GmbH. Industry-linked
Safety
Post-marketing (Germany, ~140M daily doses): mainly hypersensitivity and GI complaints. Observational German data: no increase in breast-cancer diagnosis (OR 1.01, industry-linked). Endometrium unchanged in trials. Contains ER-β–active compounds.
Ranked products that contain it
| Product | Amount per day | Score | $/day |
|---|---|---|---|
| Nature's Bounty Optimal Solutions Advanced Menopause Relief | Rhapontic rhubarb extract ERr 731: 4 mg | 56.7 | $0.67 |
| Estroven Complete Multi-Symptom Menopause Relief | Rhapontic rhubarb root extract ERr 731: 4 mg | 55.0 | $0.71 |
| Estroven Complete Menopause Relief Gummies | Rhapontic rhubarb root extract ERr 731: 4 mg | 50.3 | $0.88 |
FAQ
Does ERr 731 rhapontic rhubarb help with menopause symptoms?
ERr 731 is a rhapontic rhubarb root extract (the active in Estroven Complete) studied in perimenopausal women for occasional hot flashes and related symptoms*. The placebo-controlled trials come from one research group. Our evidence grade is C (C+ for perimenopause). Dubey 2024 MA (4 studies, 390 women; industry-affiliated authors): MRS -15 points vs control.
Does The Menopause Society recommend ERr 731 rhapontic rhubarb?
Not recommended (Level II) – placebo-arm retention only 12.7% in key RCT; open-label study. The 2023 nonhormone statement recommends no dietary supplement for hot flashes; talk to a clinician about hormone therapy and prescription options.
Is ERr 731 rhapontic rhubarb safe?
Post-marketing (Germany, ~140M daily doses): mainly hypersensitivity and GI complaints. Observational German data: no increase in breast-cancer diagnosis (OR 1.01, industry-linked). Endometrium unchanged in trials. Contains ER-β–active compounds. Supplements are not FDA-approved before sale; ask a clinician or pharmacist, especially if you take medication.
Sources
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.